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ORIGINAL ARTICLEMulticenter Phase II Study of Intravenous and Intraperitoneal
Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinomaitoneal MetastasisPatients With PerSohei Satoi, MD, Tsutomu Fujii, MD,y Hiroaki Yanagimoto, MD, Fuyuhiko Motoi, MD,z
Masanao Kurata, MD,§ Naminatsu Takahara, MD, Suguru Yamada, MD,y Tomohisa Yamamoto, MD,
Masamichi Mizuma, MD,z Goro Honda, MD,jj Hiroyuki Isayama, MD, Michiaki Unno, MD,z
Yasuhiro Kodera, MD,y Hironori Ishigami, MD, and Masanori Kon, MDObjective: To evaluate the clinical efficacy and tolerability of intravenous
(i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, ‘‘an oral
fluoropyrimidine derivative containing tegafur, gimestat, and otastat potass-
ium’’ in chemotherapy-naive pancreatic ductal adenocarcinoma (PDAC)
patients with peritoneal metastasis.
Background: PDAC patients with peritoneal metastasis (peritoneal deposits
and/or positive peritoneal cytology) have an extremely poor prognosis. An
effective treatment strategy remains elusive.
Methods: Paclitaxel was administered i.v. at 50mg/m2 and i.p. at 20mg/m2
on days 1 and 8. S-1 was administered at 80mg/m2/d for 14 consecutive days,
followed by 7 days of rest. The primary endpoint was 1-year overall survival
(OS) rate. The secondary endpoints were antitumor effect and safety
(UMIN000009446).
Results: Thirty-three patients who were pathologically diagnosed with the
presence of peritoneal dissemination (n ¼ 22) and/or positive peritoneal
cytology (n ¼ 11) without other organ metastasis were enrolled. The tumor
was located at the pancreatic head in 7 patients and the body/tail in 26 patients.
The median survival time was 16.3 (11.47–22.57) months, and the 1-year
survival rate was 62%. The response rate and disease control rate in assessable Copyright © 2016 Wolters Klu
patients were 36% and 82%, respectively. OS in 8 patients who underwent
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Annals of Surgery  Volume 265, Number 2, February 2017conversion surgery was significantly higher than that of nonsurgical patients
(n¼ 25, P¼ 0.0062). Grade 3/4 hematologic toxicities occurred in 42% of the
patients and nonhematologic adverse events in 18%. One patient died of
thrombosis in the superior mesenteric artery.
Conclusions: This regimen has shown promising clinical efficacy with
acceptable tolerability in chemotherapy-naive PDAC patients with peritoneal
metastasis.
Keywords: intraperitoneal chemotherapy, paclitaxel, pancreatic ductal
adenocarcinoma, peritoneal metastasis, S-1
(Ann Surg 2017;265:397–401)
P ancreatic ductal adenocarcinoma (PDAC) continues to have adismal prognosis with a 5-year survival rate of <5% even in the
modern era.1,2 The median survival time (MST) of patients with
distant organ metastasis, including peritoneal metastasis,3 is
extremely poor at less than 12 months. Moreover, the presence of
peritoneal metastasis is associated with development of intestinal
obstruction, massive ascites, and malnutrition, leading to poor
performance status,4 which, in turn, deprives the patients of the
opportunity to receive chemotherapy.5 MST of these patients has
been reported to be 6 weeks from a population-based study in the
Netherlands,3 and 7 weeks in another series of 73 patients with
malignant ascites.4 Pharmacokinetic studies revealed that anticancer
drugs administered systemically do not necessarily enter the perito-
neal cavity. Compared with systemic chemotherapy, intraperitoneal
(i.p.) chemotherapy seems to be advantageous for treatment of
peritoneal dissemination due to a high drug concentration in the
peritoneal cavity to directly contact tumor nodules.6–10
The clinical effects of i.p. paclitaxel (PTX) in patients with
peritoneal metastasis have been favorably reported in clinical trials for
ovarian cancer,6,7 gastric cancer,8,9 and even PDAC.10 Most notably,
Ishigami et al8 conducted a phase II study of weekly intravenous (i.v.)
and i.p. PTXwithS-1 in gastric cancerwith peritonealmetastases,with
remarkable results such as overall response rate (ORR) of 56%,
disappearance or marked decrease in malignant ascites in 62%, and
1-year overall survival (OS) rate of 78%. Kamei et al11 demonstrated
that i.p. administration of PTX nanoparticles resulted in high accumu-
lation in disseminated nodules, presumably due to its superior pene-
trating activity directly into malignant tissue in a mouse. Thus, i.p.
chemotherapy using PTX is considered to be an ideal therapeutic
approach for peritoneal carcinomatosis from the viewpoint of drug
delivery. In addition, S-1 is an oral fluoropyrimidine derivative which
significantly prevented peritoneal carcinomatosis in gastric cancer in
the postoperative adjuvant setting, and has shown efficacy also in the
treatment of pancreatic cancer.
Therefore, we have conducted a phase II study in a multicenterwer Health, Inc. All rights reserved.
setting to evaluate the clinical efficacy and tolerability of i.v. and i.p.
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jaundice before the enrollment.
TABLE 1. Patient Characteristics
Parameters
All Eligible Patients
(n ¼ 33)
Age (range), y 69 (42–79)
Male:female 14:19
Body mass index (range) 21.42 (13.34–24.17)
Performance status (%), 0:1 20 (61%): 13 (39%)
Tumor location, head:body/tail 7:26
Tumor diameter (range), mm 40 (22–105)
Resectable: borderline resectable: unresectable 11:3:19
Ascites, :þ 18:15 (45%)
Peritoneal dissemination, :þ 11:22 (67%)
Peritoneal (washing) cytology, :þ 1:32 (97%)
Albumin (range), g/L 3.9 (2.7–4.3)
CA19–9 (range), U/mL 344 (1–25850)
Duration of protocol therapy
(range), mo
8.8 (0.8–22.6)
The data are expressed as median and range.
Resectability status was defined according to the NCCN guideline.
Satoi et al Annals of Surgery  Volume 265, Number 2, February 2017PTX combined with S-18 in PDAC patients with peritoneal meta-
stasis, but without other distant organ metastases.
METHODS
Patient Recruitment
FromDecember 2012 toMarch 2015, 33 patients were enrolled
in this phase II study at 7 Japanese centers. The eligibility criteria were
as follows: histologically proven PDAC; presence of cancer cells on
peritoneal cytology performed using staging laparoscopy in patients
with radiographically defined unresectable locally advanced PDAC, or
peritoneal dissemination in all types of PDAC on staging laparoscopy
or open laparotomy; chemotherapy-naive; EasternCooperativeOncol-
ogy Group performance status 0 to 1; adequate bone marrow function
(leukocyte count 3500–12,000/mm3, hemoglobin >8.0 g/dL, and
platelet count >100,000/mm3); adequate liver function (serum total
bilirubin<2.0mg/dL and serum transaminases<150 IU/L); adequate
renal function (serum creatinine<1.2mg/dL); age>20 years and<80
years. The exclusion criteria were as follows: presence ofmetastasis in
other distant organs such as the liver, lungs, bone or others, positive
peritoneal washing cytology in patients with resectable or borderline
resectable PDAC; other active concomitantmalignancies; other severe
medical conditions. Written informed consent was obtained from all
patients. This study was conducted in accordancewith the Declaration
of Helsinki, and the study protocol was approved by the institutional
review board of the affiliated hospital. The registration number of this
clinical trial is UMIN000009446.
Treatment
On diagnosing peritoneal dissemination or positive peritoneal
cytology during staging laparoscopy or open laparotomy, a peritoneal
access port was implanted in the lower abdomen, with a catheter placed
in the pelvic cavity. S-1was administered orally twice daily at a dose of
80mg/m2/d for 14 consecutive days, followed by 7 days of rest. PTX
was administered i.v. at a dose of 50mg/m2 and i.p. at 20mg/m2 on days
1 and 8. These dosages had been determined by a phase I study in gastric
cancer,22 and the safety at the same dosages was confirmed in a
feasibility study involving 6 patients with peritoneal metastasis from
pancreatic cancer. PTX was diluted in 1L of normal saline and
administered through the implanted peritoneal access port over 1 hour
concurrently with i.v. infusion after standard premedication. The treat-
ment course was repeated every 3 weeks until observation of unac-
ceptable toxicity, disease progression, or surgery. Surgical resection
(conversion surgery)wasperformedat adiscretionof the surgeonswhen
exceptional response to the chemotherapy was observed. Although the
criteria for conversion to surgery had not been prespecified in the
protocol, there had been a consensus among the participating investi-
gators that a patient who fulfilled all of the following without deteriora-
tion in the performance status could be indicated for surgical resection:
tumor remission was observed by the contrast-enhanced computed
tomography (CT) in case it had been unresectable locally advanced
tumor, tumor markers decreased, peritoneal washing cytology turned
negative in case it had been positive, and peritoneal deposits became
invisible by the staging laparoscopy in case it had been observed at the
time of inclusion into the trial. Although there were no strict rules
regarding the number of courses or the duration of chemotherapy to be
given before surgery, our previous finding that the interval longer than
8 months between the initial treatment and surgical resection was
associated with favorable prognosis in PDAC patients with initially
unresectable disease23 had been shared by the investigators.
Primary and Secondary Endpoints
The primary endpoint was 1-year OS rate, and the secondary Copyright © 2016 Wolters Kluw
endpoints were ORR, frequency of negative peritoneal washing
398 | www.annalsofsurgery.comcytology, ascites-onset rate within 1 year after initial treatment,
resection rate, and safety. Objective tumor responses were evaluated
every 2 months during the study, and classified based on the
Response Evaluation Criteria in Solid Tumors (RECIST) guide-
lines.12 To evaluate the antitumor effects on peritoneal metastases,
peritoneal washing cytology through a peritoneal access port was
examined using Papanicolaou and May-Giemsa staining every
2 months. Toxicity was monitored weekly and graded according
to the National Cancer Institute–Common Terminology Criteria for
Adverse Events version 4.0.
Statistical Analysis
The sample size was calculated as follows. An estimated
1-year survival rate of patients with metastatic PDAC was 25%.
Assuming a null hypothesis of 25% and an alternative hypothesis of
45% with 1-sided type I error of 0.05 and power of 0.8, with an
accrual time of 2 years and follow-up of 1 year after closure of
recruitment, enrollment of 24 patients was required. Continuous
variables were expressed as median and range. The MST was
estimated using the Kaplan-Meier method. Patients alive at the time
of follow-up were censored. The last follow-up date was December
2015. Statistical analyses were performed using JMP statistical
discovery software (JMP version 11.0, SAS Institute, Cary, NC).
A P value <0.05 was considered statistically significant.
RESULTS
Clinical Background
As shown in Table 1, 33 patients were enrolled, including 22
patients with peritoneal dissemination (of which peritoneal washing
cytology was positive in 21 patients), and 11 patients with positive
peritoneal washing cytology. Malignant ascites was observed in 15
patients on laparoscopy or laparotomy. Primary tumors were cate-
gorized as unresectable locally advanced disease in 19 patients,
borderline resectable in 3 patients, and resectable in 11 patients,
respectively. Median age was 69 years (range 42–79), and the male-
to-female ratio was 14:19. The tumor was located at the pancreatic
head in 7 patients and the body/tail in 26 patients, and the median
diameter of the tumor was 40 (22–105)mm. The median carbo-
hydrate antigen 19–9 (CA19–9) level was 344 (1–25,850)U/mL at
the baseline. Performance status was 0 in 20 patients and 1 in 13
patients. Five patients underwent biliary drainage due to obstructiveer Health, Inc. All rights reserved.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Overall survival curve of 33 PDAC patients with
peritoneal metastasis. The median survival time was 16.3
months, and 1- and 2-year survival rates were 62% and
23%, respectively.
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This regimen was administered for a median of 8.8 (0.8–22.6)
months. As shown in Figure 1, 23 out of 33 patients have already died,
with a median observation period of 13.4 (8.2–32.6) months or until
death. Thirty-one out of 33 patients were followed up for at least 12
months. The MSTwas 16.3 (11.47–22.57) months, and 1 and 2-year
OS rateswere 62%and23%, respectively (Fig. 1).As shown inTable 2,
the ORR byRECIST criteria was 36% and the disease control ratewas
82%. Peritoneal washing cytology turned negative in 18 of 33 patients
(55%). During treatment, the median rate of CA19–9 decrease was
51%, and normalization of CA19–9 was observed in 35% of patients.
Malignant ascites was observed in 15 of 33 patients at diagnosis of
peritoneal metastasis. During treatment, ascites disappeared in 9 of 15
patients within 1 year of initial treatment; the remaining 6 patients
currently have malignant ascites. Another 4 patients newly developed
malignant ascites. Overall, 10 out of 33 patients (30%) had malignant
ascites within 1 year of initial treatment.
Conversion Surgery
Of the 33 patients, 8 patients (24%) including 5 patients who
had peritoneal dissemination and 3 patients with positive peritoneal Copyright © 2016 Wolters Klu
washing cytology status plus unresectable locally advanced cancer
TABLE 2. Clinical Responses
Parameters
All Eligible
Patients (n ¼ 33)
Minimum value of CA19–9 (range), U/mL 30.2 (0.7–6.548)
Decreased rate of CA19–9 (range), % 51 (59.3–99.7)
Normalization of CA19–9, % 9/26 (35)
Tumor response
Complete response, % 0 (0)
Partial response, % 12 (36)
Stable disease, % 15 (46)
Progressive disease, % 2 (6)
Not evaluated, % 4 (12)
Peritoneal cytology, turned negative, % 18 (55)
 2016 Wolters Kluwer Health, Inc. All rights reserved.underwent pancreatectomy (Table 3). All patients underwent surgical
resection more than 8 months after the initiation of chemotherapy.
Distal pancreatectomy with celiac axis resection was performed in 2
patients, radical antegrade modulated pancreatosplenectomy was
performed in 2 patients, distal pancreatectomy was performed in
2 patients, total pancreatectomy with portal vein resection was
performed in 1 patient, and pancreatoduodenectomy with portal vein
resection in 1 patient. Five out of 8 patients underwent concomitant
major artery and/or portal vein resection. The consequences were R0
resection in 6 patients and R1 resection in 2 patients. No in-hospital
deaths occurred in patients who underwent surgical resection. Patho-
logical staging revealed T3N1M0 in 6 patients and T3N0M0 in 2
patients. Evans classification13 was IIA in 6 patients and IIB in
2 patients. As shown in Figure 2, OS of patients who underwent
conversion surgery was significantly better than that of patients who
did not undergo conversion surgery (P¼ 0.0038), and MSTwas also
longer (27.8 vs 14.2 mo, respectively).
Adverse Event Profile
Overall results are listed in Table 4, grade 3/4 hematologic
adverse events included neutropenia (42%), leukopenia (18%),
febrile neutropenia (6%), and anemia (3%). Grade 3/4 nonhemato-
logic adverse events included appetite loss in 12%, nausea in 9%,
vomiting and diarrhea in 6%, and mucositis in 6%. A total of 3
patients discontinued treatment after 1 month. One of these patients
died of superior mesenteric arterial thrombosis after the first infusion
of this regimen, and this case was regarded as a treatment-related
death. Other severe adverse events were anaphylactic reaction during
the first infusion of this regimen and severe mucositis and diarrhea.
Complications related to the peritoneal access device presented as
infection of the i.p. catheter in 1 patient, and dislocation of the device
in 2 patients.
DISCUSSION
Recent progress in chemotherapy has provided an improved
prognosis in patients with unresectable PDAC.14,16 In particular,
MST of patients with metastatic disease has increased up to
11.5 months with the FOLFIRINOX regimen15 and 8.5 months with
the gemcitabine þ nab-PTX regimen.14 ORR of FOLFIRINOX
(oxaliplatin, irinotecan, 5-FU, and leucovorin) and gemcitabine þ
nab-PTX regimen was 31%15 and 23%,14 respectively. Given the
pharmacokinetics of intravenously administered agent, it remains
doubtful whether these advances in systemic treatment also translate
into improvements in the outcome of patients with peritoneal meta-
stasis. In reality, prognosis of PDAC patients with peritoneal meta-
stasis remains extremely poor (MST 6–7 wks).3,4,17–19
A standard chemotherapy regimen for unresectable PDAC in
Japan is S-1 (MST 9.7 mo), survival of which was revealed to be
noninferior to that of gemcitabine (MST 8.8 mo) in the GEST study
(randomized phase III study of Gemcitabine plus S-1, S-1 alone, or
Gemcitabine alone in patients with locally advanced and metastatic
pancreatic cancer).16 A few authors reported i.v. PTX as a potential
treatment option in patients with gemcitabine-refractory pancreatic
cancer.20–22 Ishigami et al8,23 established i.v./i.p. PTXþ S-1 therapy
in gastric cancer patients with peritoneal metastasis in a phase I/II
study. These investigators suggested that i.p. administration of anti-
cancer drugs enabled an extremely high concentration of drugs to
directly contact the target cancer lesions in the peritoneal cavity due
to its large molecular weight and fat solubility.8,23
The present study focused on the clinical efficacy and feasi-
bility of i.v./i.p. PTX þ S-1 therapy in chemotherapy-naive patients
with peritoneal metastasis without metastasis in other distant sites.
The MST was 16.3 months (11.47–22.57), and the 1-year OS rate
18wer Health, Inc. All rights reserved.
was 62%. Ferrone et al reported an MST of 7 months in PDAC
www.annalsofsurgery.com | 399
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FIGURE 2. Comparison of survival curves between patients
who underwent conversion surgery (n ¼ 8, solid line) and
no surgery (n ¼ 25, broken line). Overall survival of patients
who underwent conversion surgery was significantly longer
than that of patients without conversion surgery (P ¼ 0.0038),
and MST was 27.8 months in the former group and 14.2
months in the latter group.
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400 | www.annalsofsurgery.compatients with peritoneal dissemination, and 6 months in patients with
locally advanced disease who had positive peritoneal washing
cytology during staging laparoscopy. Our previous report also
revealed that ascites occurred within 1-year after initiation of chemo-
therapy in approximately 70% of patients with peritoneal metastasis
diagnosed by staging laparoscopy for radiographically defined
locally advanced PDAC.5 Considering that the patients with perito-
neal metastasis generally have a particularly poor prognosis, the
present survival results are encouraging.
In the current study, the high response and disease control
rates (36% and 82%, respectively) in addition to the efficacy in
eliminating peritoneal deposits and intraperitoneal free cancer cells
allowed surgeons to perform conversion surgery in selected patients.
Surprisingly, the rate of conversion surgery was 24% in this study,
and pathological response of some extent was observed in all patients
who underwent conversion surgery. Moreover, the MST in patients
who underwent conversion surgery was 27.8 months, which was
comparable to that in patients with resectable PDAC. The MST after
conversion surgery for PDAC has actually been reported to reach 30
to 52 months.24–28 Unfortunately, only a small fraction of PDAC is
eligible for conversion surgery, and in our experience, only 13 of
130 patients (10%) with initially unresectable locally advanced
PDAC underwent surgical resection after a favorable response to
chemo(radio)therapy.28 Thus, the i.v./i.p. PTX þ S-1 combination
has shown remarkable performance, both in terms of the conversion
rate and outcome of patient who received conversion surgery. This
regimen therefore has the potential to control not only peritoneal
metastasis but also the primary tumor.
Although 1 treatment-related death due to thrombosis in the
superior mesenteric artery and 1 anaphylactic reaction were
observed, most of the adverse events observed in this study were
similar to those seen in gastric cancer patients with peritoneal
metastasis.8 The median duration of treatment was 8.8 months iner Health, Inc. All rights reserved.
the present study, which was relatively longer than the 2.6 to 4.3
 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Profile of Adverse Events
Grading by CTCAEv4.0 1 2 3 4 3/4
Leucocytopenia 5 10 4 2 18%
Neutropenia 0 4 8 6 42%
Febrile neutropenia 0 0 1 1 6%
Anemia 12 11 1 0 3%
Thrombocytop enia 4 2 1 1 6%
Liver function 10 1 0 0 0%
General fatigue 5 2 1 0 3%
Appetite loss 10 3 4 0 12%
Nausea 7 1 3 0 9%
Vomiting 1 1 2 0 6%
Diarrhea 5 1 2 0 6%
Skin rash 4 1 0 0 0%
Mucositis oral (stomatitis) 5 1 2 0 6%
Peripheral neuropathy 6 2 0 0 0%
Alopecia 14 4 0 0 0%
Edema 2 1 0 0 0%
Pneumonia 1 1 0 0 0%
Dysgeusia 8 0 0 0 0%
Anaphylaxis 0 0 0 1 3%
Annals of Surgery  Volume 265, Number 2, February 2017 Study of Intravenous and Intraperitoneal Paclitaxel With S-1months previously reported in the GEST study.16 Taken together, the
i.v./i.p. PTX þ S-1 combination was considered relatively safe
and feasible.
Even with these highly promising results, this study can only
be hypothesis-generating at this time, given the small sample size and
the nonrandomized nature. Sustainable efforts are warranted to
conduct a decently designed randomized clinical trial to confirm
efficacy of this combination in the subset of PDAC patients with high
risk of death due to the peritoneal disease.
In conclusion, i.v./i.p. PTX þ S-1 provides promising and
encouraging clinical efficacy and acceptable tolerability in chemo-
therapy-naive PDAC patients with peritoneal metastasis.
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